# AstraZeneca

Organization · id `cardio:astrazeneca` · Cardiovascular Atlas · release `5dcd9b263fe17744` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

## In plain language

A pharmaceutical company. It sponsored the DAPA-HF and DELIVER trials of dapagliflozin. The US regulator's record for Farxiga names an AstraZeneca company as the sponsor of the application.

## Technical summary

Research Organization Registry record 04r9x1a08 lists AstraZeneca (United Kingdom), a company and funder, in Cambridge, England. DAPA-HF (NCT03036124) and DELIVER (NCT03619213) name AstraZeneca as lead sponsor, with sponsor class industry. The openFDA record for NDA202293 names ASTRAZENECA AB as the application sponsor and lists AstraZeneca Pharmaceuticals LP as a manufacturer name; the Research Organization Registry lists AstraZeneca (Sweden) among its child organizations. This page does not say how these names relate.

## Connected pages

- Manufactures: Dapagliflozin (Farxiga) (`cardio:farxiga`)
- Sponsors: DAPA-CKD: dapagliflozin in chronic kidney disease (`cardio:dapa-ckd`)
- Sponsors: DAPA-HF (`cardio:dapa-hf`)
- Sponsors: DECLARE-TIMI 58: dapagliflozin and cardiovascular outcomes in type 2 diabetes (`cardio:declare-timi-58`)
- Sponsors: DELIVER (`cardio:deliver`)

## Provenance

Content hash: e62496f287ac5d6fe4f58969edfd4357c8ec6785a1c43035bd6746e1c09ae6f0
Last substantive edit: 2026-10-15
Evidence last checked: 2026-10-14